Macquarie Group Ltd. Lowers Holdings in Bio-Rad Laboratories, Inc. (NYSE:BIO)
Macquarie Group Ltd. Lowers Holdings in Bio-Rad Laboratories, Inc. (NYSE:BIO)
Macquarie Group Ltd. lowered its stake in Bio-Rad Laboratories, Inc. (NYSE:BIO – Get Rating) by 9.6% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 2,252 shares of the medical research company's stock after selling 238 shares during the period. Macquarie Group Ltd.'s holdings in Bio-Rad Laboratories were worth $940,000 as of its most recent SEC filing.
Several other hedge funds and other institutional investors have also recently modified their holdings of the business. Gabelli Funds LLC increased its stake in Bio-Rad Laboratories by 2.8% during the 3rd quarter. Gabelli Funds LLC now owns 36,800 shares of the medical research company's stock valued at $15,351,000 after purchasing an additional 1,000 shares in the last quarter. Zacks Investment Management raised its stake in shares of Bio-Rad Laboratories by 722.0% during the 3rd quarter. Zacks Investment Management now owns 6,469 shares of the medical research company's stock valued at $2,698,000 after buying an additional 5,682 shares during the last quarter. Royal Bank of Canada lifted its holdings in shares of Bio-Rad Laboratories by 16.8% in the 3rd quarter. Royal Bank of Canada now owns 66,398 shares of the medical research company's stock valued at $27,697,000 after buying an additional 9,543 shares during the period. Eaton Vance Management grew its holdings in Bio-Rad Laboratories by 1.6% during the third quarter. Eaton Vance Management now owns 6,452 shares of the medical research company's stock worth $2,691,000 after acquiring an additional 104 shares during the period. Finally, Tudor Investment Corp Et Al boosted its position in Bio-Rad Laboratories by 1,241.5% in the 3rd quarter. Tudor Investment Corp Et Al now owns 12,583 shares of the medical research company's stock worth $5,249,000 after purchasing an additional 11,645 shares in the last quarter. 64.35% of the stock is currently owned by hedge funds and other institutional investors.
Get Bio-Rad Laboratories alerts:Insider Activity at Bio-Rad Laboratories
In related news, EVP Timothy S. Ernst sold 1,746 shares of the company's stock in a transaction dated Wednesday, March 8th. The stock was sold at an average price of $486.43, for a total value of $849,306.78. Following the completion of the sale, the executive vice president now owns 2,671 shares in the company, valued at $1,299,254.53. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Insiders own 27.40% of the company's stock.
Bio-Rad Laboratories Stock Performance
Shares of NYSE BIO opened at $478.24 on Monday. The company has a debt-to-equity ratio of 0.12, a quick ratio of 4.29 and a current ratio of 5.55. The stock has a fifty day moving average price of $465.39 and a two-hundred day moving average price of $436.90. Bio-Rad Laboratories, Inc. has a 1 year low of $344.63 and a 1 year high of $607.54. The firm has a market cap of $14.16 billion, a P/E ratio of -3.94 and a beta of 0.93.
Bio-Rad Laboratories (NYSE:BIO – Get Rating) last issued its quarterly earnings data on Thursday, February 16th. The medical research company reported $3.31 earnings per share for the quarter, missing the consensus estimate of $3.45 by ($0.14). The business had revenue of $730.29 million for the quarter, compared to the consensus estimate of $741.01 million. Bio-Rad Laboratories had a negative net margin of 129.66% and a positive return on equity of 4.59%. Bio-Rad Laboratories's revenue was down .3% compared to the same quarter last year. During the same period in the previous year, the business posted $3.21 EPS. Research analysts forecast that Bio-Rad Laboratories, Inc. will post 15.91 EPS for the current fiscal year.
Analysts Set New Price Targets
Several analysts have commented on the company. Royal Bank of Canada raised their price objective on Bio-Rad Laboratories from $571.00 to $579.00 and gave the company an "outperform" rating in a report on Friday, February 17th. Credit Suisse Group lifted their target price on shares of Bio-Rad Laboratories from $640.00 to $680.00 and gave the company an "outperform" rating in a research report on Friday, February 17th. TheStreet upgraded Bio-Rad Laboratories from a "d+" rating to a "c" rating in a research report on Thursday, February 16th. Finally, StockNews.com upgraded Bio-Rad Laboratories from a "hold" rating to a "buy" rating in a report on Monday, February 20th. Five analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company has a consensus rating of "Buy" and a consensus price target of $664.75.
Bio-Rad Laboratories Company Profile
(Get Rating)
Bio-Rad Laboratories, Inc engages in the development and production of specialty chemicals used in biochemical, pharmaceutical, and other life science research applications. It operates through the Life Sciences and Clinical Diagnostics segments. The Life Science segment develops, manufactures, and markets reagents, apparatus, and laboratory instruments.
Featured Stories
- Get a free copy of the StockNews.com research report on Bio-Rad Laboratories (BIO)
- What the SVB Financial Collapse Means for U.S. Banks
- MarketBeat Week in Review – 3/6 – 3/10
- 2 Offshore Drilling Stocks Set to Extract Big Profits
- Three Staples Stocks With Double-Digit Upside Ahead
- Can Investors Trust Consumers to Lift American Outdoor Brands?
Receive News & Ratings for Bio-Rad Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bio-Rad Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.
麥格理集團(Macquarie Group Ltd.)在提交給美國證券交易委員會(Securities And Exchange Commission)的最新Form 13F檔案中稱,該公司第三季度將其在Bio-Rad實驗室的持股比例降低了9.6%。該機構投資者在此期間出售了238股後,持有這家醫學研究公司2252股股票。截至最近提交給美國證券交易委員會的檔案,麥格理集團持有的Bio-Rad實驗室股份價值940,000美元。
其他幾家對沖基金和其他機構投資者最近也調整了對該公司的持股。Gabelli Funds LLC在第三季度增持了Bio-Rad實驗室2.8%的股份。Gabelli Funds LLC現在持有這家醫學研究公司36,800股票,價值15,351,000美元,上個季度又購買了1,000股。扎克斯投資管理公司在第三季度增持了722.0%的Bio-Rad實驗室股份。扎克斯投資管理公司現在擁有6469股這家醫療研究公司的股票,價值269.8萬美元,在上個季度又購買了5682股。加拿大皇家銀行在第三季度增持了Bio-Rad實驗室16.8%的股份。加拿大皇家銀行現在持有這家醫學研究公司66,398股股票,價值27,697,000美元,在此期間又購買了9,543股。第三季度,伊頓·萬斯管理公司對Bio-Rad實驗室的持股增加了1.6%。伊頓·萬斯管理公司(Eaton Vance Management)在此期間額外收購了104股,現在擁有6452股這家醫療研究公司的股票,價值269.1萬美元。最後,都鐸投資公司等人在第三季度將其在Bio-Rad實驗室的頭寸提高了1241.5%。都鐸投資公司等人在上個季度購買了11,645股後,現在擁有12,583股這家醫學研究公司的股票,價值5,249,000美元。64.35%的股票目前由對沖基金和其他機構投資者持有。
到達Bio-Rad實驗室警報:Bio-Rad實驗室的內部活動
在相關新聞中,執行副總裁蒂莫西·S·恩斯特在3月8日星期三的交易中出售了1,746股該公司股票。這只股票的平均售價為486.43美元,總價值為849,306.78美元。出售完成後,執行副總裁總裁現在擁有該公司2671股,價值129.9254.53美元。這筆交易是在提交給美國證券交易委員會的一份檔案中披露的,該檔案可在美國證券交易委員會網站。內部人士持有該公司27.40%的股份。
Bio-Rad實驗室股票表現
週一,紐約證券交易所BIO的股價開盤報478.24美元。該公司的負債權益比率為0.12,速動比率為4.29,流動比率為5.55。該股的50日移動均線價格為465.39美元,200日移動均線價格為436.90美元。Bio-Rad實驗室公司的一年低點為344.63美元,一年高位為607.54美元。該公司的市值為141.6億美元,本益比為-3.94,貝塔係數為0.93。
Bio-Rad實驗室(紐約證券交易所代碼:Bio-Get Rating)最近一次發佈季度收益數據是在2月16日星期四。這家醫學研究公司公佈本季度每股收益為3.31美元,低於普遍預期的3.45美元(0.14美元)。該業務本季度的收入為7.3029億美元,而普遍預期為7.4101億美元。Bio-Rad實驗室的淨利潤率為負129.66%,股本回報率為正4.59%。與去年同期相比,Bio-Rad實驗室的收入下降了0.3%。去年同期,該業務公佈的每股收益為3.21美元。研究分析師預測,Bio-Rad實驗室公司本財年每股收益將達到15.91美元。
分析師設定新的價格目標
幾位分析師對該公司發表了評論。加拿大皇家銀行將Bio-Rad實驗室的目標價從571.00美元上調至579.00美元,並在2月17日星期五的一份報告中給出了該公司“跑贏大盤”的評級。瑞士信貸集團將Bio-Rad實驗室股票的目標價從640.00美元上調至680.00美元,並在2月17日星期五的一份研究報告中給出了該公司“跑贏大盤”的評級。華爾街在2月16日星期四的一份研究報告中將Bio-Rad實驗室的評級從“d+”上調至“c”。最後,在2月20日星期一的一份報告中,StockNews.com將Bio-Rad實驗室的評級從持有上調至買入。根據MarketBeat.com的數據,五位分析師對該股的評級為買入,該公司的共識評級為買入,共識目標價為664.75美元。
Bio-Rad實驗室公司簡介
(獲取評級)
Bio-Rad實驗室公司致力於開發和生產用於生化、製藥和其他生命科學研究應用的特殊化學品。它通過生命科學和臨床診斷部門開展業務。生命科學部門開發、製造和銷售試劑、儀器和實驗室儀器。
專題報道
- 免費獲取StockNews.com關於Bio-Rad實驗室的研究報告(BIO)
- SVB金融崩潰對美國銀行意味著什麼
- 市場回顧周-3/6/3/10
- 2個近海鑽探公司將大賺一筆
- 未來有望實現兩位數上漲的三隻史泰博股票
- 投資者能信任消費者來提升美國戶外品牌嗎?
每天收到Bio-Rad實驗室的新聞和評級-在下面輸入您的電子郵件地址,通過MarketBeat.com的免費每日電子郵件時事通訊接收對Bio-Rad實驗室和相關公司的最新新聞和分析師評級的每日簡要摘要。
譯文內容由第三人軟體翻譯。
風險及免責聲明
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用瀏覽器的分享功能,分享給你的好友吧